Abstract
Angiogenesis is necessary for tumor growth, without which a tumor can not grow beyond a few millimeters in diameter. This review summarizes the current status on the research of peptide Arg-Gly-Asp (RGD) and Arg-Arg-Leu (RRL) as well as its derivatives applied in tumor angiogenesis imaging and targeted therapy with single photon emission tomography (SPECT) and positron emissiontomography (PET). Peptide RGD sequence Arg-Gly-Asp targeted and combined to integrin αvβ3 which has been overexpressed on tumor endothelial cells and many different tumor cellsis a robust site for tumor angiogenesis molecular imaging and targeted therapy. The vari-ous derivatives of RGD were focused on optimizing its biological characteristics including affinity, targeting efficacy and pharmacoki-netics. The other alternative novel tumor angiogenesis molecular imaging agent is RRL peptide which targeted to tumor derived endothe-lial cells and then applied to visualize tumor angiogenesis with enhanced ultrasonic imaging, optical imaging and SPECT in animal. These novel peptide agents can have promising applications for tumor angiogenesis imaging and antiangiogenic tumor therapy.
Keywords: Tumor angiogenesis, Vascular endothelial growth factor, Vascular endothelial growth factor receptor, Integrin αvβ3, Peptide RGD, Peptide RRL, Tumor molecular imaging, Targeted therapy, tumor growth, ultrasonic imaging
Current Pharmaceutical Design
Title: A Concise Review of Current Radiopharmaceuticals in Tumor Angiogenesis Imaging
Volume: 18 Issue: 8
Author(s): Xia Lu and Rong Fu Wang
Affiliation:
Keywords: Tumor angiogenesis, Vascular endothelial growth factor, Vascular endothelial growth factor receptor, Integrin αvβ3, Peptide RGD, Peptide RRL, Tumor molecular imaging, Targeted therapy, tumor growth, ultrasonic imaging
Abstract: Angiogenesis is necessary for tumor growth, without which a tumor can not grow beyond a few millimeters in diameter. This review summarizes the current status on the research of peptide Arg-Gly-Asp (RGD) and Arg-Arg-Leu (RRL) as well as its derivatives applied in tumor angiogenesis imaging and targeted therapy with single photon emission tomography (SPECT) and positron emissiontomography (PET). Peptide RGD sequence Arg-Gly-Asp targeted and combined to integrin αvβ3 which has been overexpressed on tumor endothelial cells and many different tumor cellsis a robust site for tumor angiogenesis molecular imaging and targeted therapy. The vari-ous derivatives of RGD were focused on optimizing its biological characteristics including affinity, targeting efficacy and pharmacoki-netics. The other alternative novel tumor angiogenesis molecular imaging agent is RRL peptide which targeted to tumor derived endothe-lial cells and then applied to visualize tumor angiogenesis with enhanced ultrasonic imaging, optical imaging and SPECT in animal. These novel peptide agents can have promising applications for tumor angiogenesis imaging and antiangiogenic tumor therapy.
Export Options
About this article
Cite this article as:
Lu Xia and Fu Wang Rong, A Concise Review of Current Radiopharmaceuticals in Tumor Angiogenesis Imaging, Current Pharmaceutical Design 2012; 18 (8) . https://dx.doi.org/10.2174/138161212799315812
DOI https://dx.doi.org/10.2174/138161212799315812 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Investigative Approach to Treatment Modalities for Squamous Cell Carcinoma of Skin
Current Drug Delivery Upregulated Long Non-coding RNA ALMS1-IT1 Promotes Neuroinflammation by Activating NF-κB Signaling in Ischemic Cerebral Injury
Current Pharmaceutical Design Crossed Cerebellar Diaschisis in Alzheimer’s Disease
Current Alzheimer Research Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity
Current Drug Targets Neuropilin-1 (NRP-1) and Magnetic Nanoparticles, a Potential Combination for Diagnosis and Therapy of Gliomas
Current Pharmaceutical Design Keeping A Breast of Recent Developments in Cancer Metabolism
Current Drug Targets Radionuclide-Labeled Peptides for Imaging and Treatment of CXCR4- Overexpressing Malignant Tumors
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Implication of Non-coding RNAs in Cancer Biology and Cellular Physiology)
Current Genomics Cannabinoids and Sensory Neurones
Current Neuropharmacology Mitochondria as Possible Pharmaceutical Targets for the Effects of Vitamin E and its Homologues in Oxidative Stress-Related Diseases
Current Pharmaceutical Design Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology Editorial [Hot Topic:Angiogenesis Agents(Executive Editor: Cezary Marcinkiewicz)]
Current Pharmaceutical Design Potential Cardio-Protective Agents: A Resveratrol Review (2000-2019)
Current Pharmaceutical Design Computational Analysis of miRNA and their Gene Targets Significantly Involved in Colorectal Cancer Progression
MicroRNA The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib
Current Pharmaceutical Design Introduction: MMPs, ADAMs/ADAMTSs Research Products to Achieve Big Dream
Anti-Cancer Agents in Medicinal Chemistry Intracellular Routing of Cytotoxic Pancreatic-Type Ribonucleases
Current Pharmaceutical Biotechnology Fighting Fire with Fire: A Patent for the Combined Application of Oncolytic Herpes Viruses and Antiangiogenic Agents in the Battle Against Human Cancers
Recent Patents on Anti-Cancer Drug Discovery Strategies for the Preparation of Bifunctional Gadolinium(III) Chelators
Current Organic Synthesis Multimodal Navigation in Glioma Surgery
Current Medical Imaging